Where the stock stands
Aurobindo Pharma Ltd., a Healthcare-sector name, was last quoted at 1663.4 against a previous close of 1667.0 - down 0.22% on the day, in a session where the Nifty itself slipped 0.16%. The 2026-08-12 close of 1667.0 left the stock 0.29% below its 52-week high of 1671.9 and 64.06% above its 52-week low of 1016.1, which places it at the very top of its one-year range.
Returns are positive across every standard window: up 3.32% over a week, 7.35% over a month, 10.2% over three months and 55.4% over the year. On the valuation figures supplied, the shares carry a price-to-earnings ratio of 25.99 and a price-to-book of 2.56 on earnings per share of 64.35, with a market capitalisation of 96232 crore and a dividend yield of 0.24%. No growth, margin or debt data accompanies those multiples.
What the smart-money flow shows
Almost nothing is here, and the specifics of that gap matter. The pack carries no futures and options positioning - no open-interest change and no long-buildup or short-buildup reading, a long buildup being fresh futures positions opened as the price rises. It names no bulk or block deals, the large negotiated trades exchanges disclose with the counterparties identified. It records no institutional buying or selling streak, and it shows no insider or promoter filings.
That is an absence in the available data rather than proof of an absence in the market itself. The consequence for a reader is the same either way: nothing on this page identifies who has been buying or selling through a year in which the stock rose 55.4%.
The technical picture
Trend markers are aligned one way. The stock sits above both its 50-day and 200-day moving averages, and the pack flags neither a golden cross nor a death cross, so that alignment is an established condition rather than a freshly formed one. RSI-14 stands at 65.5 - the relative strength index, a momentum gauge that rises as recent gains outweigh recent declines - firm, without reaching the extremes usually labelled overbought.
Volume is the discordant note. Relative volume of 0.78 means the session traded at roughly three-quarters of the stock's own recent norm. Arriving within 0.29% of a 52-week high on below-average turnover is a thinner advance than the price line alone conveys, though a single session's volume proves little.
Catalysts and what to watch
Two exchange filings are the hardest facts on the list. Dated 2026-08-13, the company intimated the incorporation of a new wholly owned subsidiary; dated 2026-08-07, it informed the exchange of a proposed merger of two wholly owned stepdown subsidiaries with a wholly owned subsidiary. No financial detail is attached to either, so their scale cannot be judged from what is here.
Four further catalyst entries, dated 2026-08-06 through 2026-08-09, are news-sourced and repeat a single headline: that the shares gained on a USFDA approval for Tofacitinib tablets. What the data establishes is that the headline ran repeatedly across those days, not the causal link it asserts, which there is no intraday price series here to test. Elsewhere in the feed, Reuters reports a rise in quarterly profit, GuruFocus summarises a Q1 2027 earnings call, Goodreturns groups the company among names with corporate actions due, and Simply Wall St. reports analysts reworking their assumptions. A sixth item concerns Merck and is unrelated to this company.
Taken together, the data establishes a stock in a sustained one-year uptrend, a fraction below its 52-week high, advancing on below-average volume, with a cluster of filings and approval headlines behind it. It does not establish who is trading it, whether any single filing moved it, or what the earnings behind that 25.99 multiple are doing.